Balyasny Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.16M | Sell |
1,505
-67,080
| -98% | -$51.4M | ﹤0.01% | 2022 |
|
|
2025
Q4 | $52.9M | Buy |
68,585
+49,733
| +264% | +$33.8M | 0.07% | 339 |
|
|
2025
Q3 | $10.6M | Sell |
18,852
-134,584
| -88% | -$76.1M | 0.01% | 1021 |
|
|
2025
Q2 | $80.6M | Buy |
153,436
+119,909
| +358% | +$66.9M | 0.12% | 202 |
|
|
2025
Q1 | $21.3M | Buy |
33,527
+4,736
| +16% | +$3.26M | 0.04% | 573 |
|
|
2024
Q4 | $20.5M | Buy |
28,791
+20,705
| +256% | +$17.4M | 0.03% | 655 |
|
|
2024
Q3 | $8.5M | Buy |
8,086
+610
| +8% | +$679K | 0.01% | 1030 |
|
|
2024
Q2 | $7.86M | Sell |
7,476
-2,126
| -22% | -$2.06M | 0.01% | 979 |
|
|
2024
Q1 | $9.24M | Sell |
9,602
-32,391
| -77% | -$30.8M | 0.02% | 962 |
|
|
2023
Q4 | $36.9M | Buy |
41,993
+40,065
| +2,078% | +$33M | 0.07% | 361 |
|
|
2023
Q3 | $1.59M | Sell |
1,928
-665
| -26% | -$523K | ﹤0.01% | 1441 |
|
|
2023
Q2 | $1.86M | Buy |
+2,593
| New | +$2M | ﹤0.01% | 1401 |
|
|
2023
Q1 | – | Sell |
-33,457
| Closed | -$25.2M | – | 3068 |
|
|
2022
Q4 | $24.1M | Buy |
+33,457
| New | +$24.7M | 0.07% | 413 |
|
|
2022
Q3 | – | Sell |
-80,763
| Closed | -$50.8M | – | 3201 |
|
|
2022
Q2 | $47.7M | Buy |
+80,763
| New | +$52.5M | 0.16% | 160 |
|
|
2021
Q3 | – | Sell |
-66,919
| Closed | -$37.4M | – | 2343 |
|
|
2021
Q2 | $37.4M | Buy |
+66,919
| New | +$33.9M | 0.18% | 131 |
|
|
2020
Q4 | – | Sell |
-30,582
| Closed | -$17.1M | – | 1632 |
|
|
2020
Q3 | $17.1M | Buy |
+30,582
| New | +$18.5M | 0.13% | 237 |
|
|
2019
Q4 | – | Sell |
-176,027
| Closed | -$48.8M | – | 1442 |
|
|
2019
Q3 | $48.8M | Sell |
176,027
-83,020
| -32% | -$24.6M | 0.34% | 62 |
|
|
2019
Q2 | $81.1M | Buy |
259,047
+155,008
| +149% | +$51.6M | 0.52% | 26 |
|
|
2019
Q1 | $42.7M | Buy |
104,039
+57,867
| +125% | +$23.8M | 0.28% | 82 |
|
|
2018
Q4 | $17.2M | Buy |
46,172
+15,898
| +53% | +$5.82M | 0.12% | 232 |
|
|
2018
Q3 | $12.2M | Buy |
30,274
+21,238
| +235% | +$8.08M | 0.06% | 425 |
|
|
2018
Q2 | $3.12M | Sell |
9,036
-165,138
| -95% | -$51.6M | 0.01% | 804 |
|
|
2018
Q1 | $60M | Sell |
174,174
-30,383
| -15% | -$10.6M | 0.25% | 88 |
|
|
2017
Q4 | $76.9M | Buy |
+204,557
| New | +$82.8M | 0.24% | 94 |
|
|
2017
Q3 | – | Sell |
-58,357
| Closed | -$28.7M | – | 2062 |
|
|
2017
Q2 | $28.7M | Buy |
58,357
+18,857
| +48% | +$8.25M | 0.12% | 235 |
|
|
2017
Q1 | $15.3M | Buy |
+39,500
| New | +$14.6M | 0.07% | 356 |
|
|
2013
Q3 | – | Sell |
-29,750
| Closed | -$6.69M | – | 692 |
|
|
2013
Q2 | $6.69M | Buy |
+29,750
| New | +$6.93M | 0.11% | 218 |
|
Other funds holding REGN
VCM
N
Balyasny Asset Management's REGN Position: Q1 2026 in Review
Balyasny Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 98% in Q1 2026, selling an estimated $51.4M and leaving 1,505 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.
Balyasny Asset Management first reported a position in REGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $81.1M in Q2 2019. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Balyasny Asset Management held 1,505 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
- Balyasny Asset Management sold 67,080 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $51.4M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2022 holding.
- Balyasny Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
- Balyasny Asset Management's Regeneron Pharmaceuticals position peaked at $81.1M in Q2 2019.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.